Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 16.93 USD -14.41% Market Closed
Market Cap: 404.5m USD
Have any thoughts about
Cartesian Therapeutics Inc?
Write Note

Intrinsic Value

RNAC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RNAC stock under the Base Case scenario is 1.87 USD. Compared to the current market price of 16.93 USD, Cartesian Therapeutics Inc is Overvalued by 89%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RNAC Intrinsic Value
1.87 USD
Overvaluation 89%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Cartesian Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RNAC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RNAC?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Cartesian Therapeutics Inc

Provide an overview of the primary business activities
of Cartesian Therapeutics Inc.

What unique competitive advantages
does Cartesian Therapeutics Inc hold over its rivals?

What risks and challenges
does Cartesian Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Cartesian Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cartesian Therapeutics Inc.

Provide P/S
for Cartesian Therapeutics Inc.

Provide P/E
for Cartesian Therapeutics Inc.

Provide P/OCF
for Cartesian Therapeutics Inc.

Provide P/FCFE
for Cartesian Therapeutics Inc.

Provide P/B
for Cartesian Therapeutics Inc.

Provide EV/S
for Cartesian Therapeutics Inc.

Provide EV/GP
for Cartesian Therapeutics Inc.

Provide EV/EBITDA
for Cartesian Therapeutics Inc.

Provide EV/EBIT
for Cartesian Therapeutics Inc.

Provide EV/OCF
for Cartesian Therapeutics Inc.

Provide EV/FCFF
for Cartesian Therapeutics Inc.

Provide EV/IC
for Cartesian Therapeutics Inc.

Show me price targets
for Cartesian Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Cartesian Therapeutics Inc?

How accurate were the past Revenue estimates
for Cartesian Therapeutics Inc?

What are the Net Income projections
for Cartesian Therapeutics Inc?

How accurate were the past Net Income estimates
for Cartesian Therapeutics Inc?

What are the EPS projections
for Cartesian Therapeutics Inc?

How accurate were the past EPS estimates
for Cartesian Therapeutics Inc?

What are the EBIT projections
for Cartesian Therapeutics Inc?

How accurate were the past EBIT estimates
for Cartesian Therapeutics Inc?

Compare the revenue forecasts
for Cartesian Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cartesian Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cartesian Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cartesian Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cartesian Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cartesian Therapeutics Inc with its peers.

Analyze the financial leverage
of Cartesian Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cartesian Therapeutics Inc.

Provide ROE
for Cartesian Therapeutics Inc.

Provide ROA
for Cartesian Therapeutics Inc.

Provide ROIC
for Cartesian Therapeutics Inc.

Provide ROCE
for Cartesian Therapeutics Inc.

Provide Gross Margin
for Cartesian Therapeutics Inc.

Provide Operating Margin
for Cartesian Therapeutics Inc.

Provide Net Margin
for Cartesian Therapeutics Inc.

Provide FCF Margin
for Cartesian Therapeutics Inc.

Show all solvency ratios
for Cartesian Therapeutics Inc.

Provide D/E Ratio
for Cartesian Therapeutics Inc.

Provide D/A Ratio
for Cartesian Therapeutics Inc.

Provide Interest Coverage Ratio
for Cartesian Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cartesian Therapeutics Inc.

Provide Quick Ratio
for Cartesian Therapeutics Inc.

Provide Current Ratio
for Cartesian Therapeutics Inc.

Provide Cash Ratio
for Cartesian Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cartesian Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cartesian Therapeutics Inc?

What is the current Free Cash Flow
of Cartesian Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cartesian Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cartesian Therapeutics Inc

Current Assets 229.1m
Cash & Short-Term Investments 219.2m
Receivables 5.8m
Other Current Assets 4.1m
Non-Current Assets 226.2m
Long-Term Investments 2m
PP&E 23.7m
Intangibles 198.8m
Other Non-Current Assets 1.7m
Current Liabilities 21.4m
Accounts Payable 517k
Accrued Liabilities 12.2m
Other Current Liabilities 8.7m
Non-Current Liabilities 433.2m
Other Non-Current Liabilities 433.2m
Efficiency

Earnings Waterfall
Cartesian Therapeutics Inc

Revenue
47.9m USD
Operating Expenses
-101.4m USD
Operating Income
-53.5m USD
Other Expenses
-195.5m USD
Net Income
-249m USD

Free Cash Flow Analysis
Cartesian Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RNAC Profitability Score
Profitability Due Diligence

Cartesian Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
ROIC is Increasing
Exceptional 1-Year Revenue Growth
Negative 3-Years Revenue Growth
30/100
Profitability
Score

Cartesian Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

RNAC Solvency Score
Solvency Due Diligence

Cartesian Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
54/100
Solvency
Score

Cartesian Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RNAC Price Targets Summary
Cartesian Therapeutics Inc

Wall Street analysts forecast RNAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNAC is 43.86 USD with a low forecast of 39.39 USD and a high forecast of 52.5 USD.

Lowest
Price Target
39.39 USD
133% Upside
Average
Price Target
43.86 USD
159% Upside
Highest
Price Target
52.5 USD
210% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RNAC?

Click here to dive deeper.

Dividends

Cartesian Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RNAC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RNAC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

404.6m USD

Dividend Yield

0%

Description

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.

Contact

MASSACHUSETTS
Watertown
65 Grove Street
+16179231400
selectabio.com

IPO

2016-06-22

Employees

58

Officers

President, CEO & Director
Dr. Carsten Brunn Ph.D.
Chief Financial Officer
Mr. Blaine T. Davis
Chief Technology Officer
Dr. Metin Kurtoglu M.D., Ph.D.
Chief Scientific Officer
Dr. Chris Jewell Ph.D.
General Counsel & Secretary
Mr. Matthew Bartholomae J.D.
Chief Medical Officer
Dr. Milos Miljkovic M.D., Ph.D.
Show More
SVP & Head of Manufacturing
Dr. Emily English Ph.D.
Senior Director of Technology
Mr. Yi Zhang Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RNAC stock?

The intrinsic value of one RNAC stock under the Base Case scenario is 1.87 USD.

Is RNAC stock undervalued or overvalued?

Compared to the current market price of 16.93 USD, Cartesian Therapeutics Inc is Overvalued by 89%.

Back to Top